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E-mail address: melles.haile@smi.se (M. HDiagnosis of smear-negative tuberculosis (TB), which is frequently seen in HIV-infected
patients, is a challenge without conventional culture methods. Since 2007, the WHO (World
Health Organization) has endorsed new or improved tests for increased and rapid diagnosis
of TB. This study was undertaken in an effort to evaluate the accuracy of two rapid culture
methods: the Microscopic Observation Drug Susceptibility assay (MODS) and Nitrate
Reductase Assay (NRA), and the molecular based test Xpert MTB/Rif (Xpert), for diagnosis
of smear-negative TB in HIV patients using the mycobacteria growth indicator tube (MGIT)
in the BACTECTM MGITTM 960 system as the reference test. 430 smear-negative patients
with presumptive TB were enrolled in a cross-sectional study at a tertiary care facility in
Uganda. Their sputum was tested on MODS, NRA, Xpert and MGIT. Of the 430 patients,
373 had complete results to compute test accuracy. Mycobacterium tuberculosis (MTB) was
detected in 43 patients by MGIT. The sensitivity and specificity were 24.4% and 98.1% for
MODS, 41.5% and 92% for NRA, 48.8% and 95.1% for Xpert, respectively. The low sensitivity
of the tests implies that additional diagnostics such as chest X-ray and conventional liquid
culture methods might still be needed to detect TB in smear-negative HIV patients. The
high specificity of the tests is useful to confirm TB in HIV patients with symptoms sugges-
tive of TB.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
The World Health Organization (WHO) estimates that 8.7 mil-
lion people develop tuberculosis (TB) each year worldwide [1].-African Society for Myco
ent of Diagnostics and V
den.
aile).Of these, 13% are co-infectedwith HIV, while of the 1.4 million
deaths that occur, 30% are HIV-related. The African region,
especially sub-Sahara Africa, accounts for 80% of the
HIV-associated TB cases worldwide. Unfortunately, diagnosisbacteriology. Published by Elsevier Ltd. All rights reserved.
accinology, Swedish Institute for Communicable Disease Control,
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which due to its relatively low sensitivity, performs poorly
in HIV-infected patients. This is owing to the paucibacillary
nature of TB in HIV-infected patients; therefore, active TB dis-
ease is often not detected by smear examination [2,3].
Culture is a more sensitive way to detect paucibacillary
forms of TB, which are common in HIV patients and children
[4]. However, in several resource-limited settings, such as in
sub-Sahara Africa, mycobacterial culture is inaccessible to
the majority of the population. Even when available, the com-
monly used solid culture on Lo¨wenstein–Jensen culture media
(L–J) is time-consuming and growth of mycobacteria is typi-
cally detected after several weeks [5]. Commonly, therefore,
diagnosis of TB in smear-negative HIV patients is made
empirically. This is associated with delayed detection and ini-
tiation of TB treatment, and a higher mortality rate compared
with patients who are smear-positive [6].
Since 2007, the pipeline for new TB diagnostics has ex-
panded. In parallel, WHO has endorsed several new tests for
increased and more rapid TB diagnoses. However, despite a
major drive to incorporate these tests into the current diag-
nostic algorithms, data of their accuracy for diagnosis of
smear-negative TB in HIV patients is still inadequate [7]. In
this study, the accuracy of a molecular test and two rapid cul-
ture methods for diagnosis of smear-negative TB in HIV pa-
tients using the mycobacteria growth indicator tube (MGIT)
in the BACTECTM MGITTM 960 system (Becton Dickinson Biosci-
ences, Sparks, MD) as the reference test was evaluated [8].
Overview of tests
The molecular test Xpert MTB/Rif (Cepheid GeneXpert Sys-
tem, Sunnyvale, CA) (Xpert) is based on quantitative real-time
PCR for detection of TB. This is the first molecular method for
TB detection to be fully automated and to integrate all the
steps required for PCR-based DNA testing. Thus, results are
reported within three hours and with high accuracy [9,10].
Both processed and unprocessed sputum can be used in this
test.
The two rapid culture methods evaluated were: the Micro-
scopic Observation Drug Susceptibility assay (MODS), and the
Nitrate Reductase Assay (NRA). The tests are described as
being low-cost and easily implemented, andWHO has recom-
mended that both can be used as direct or indirect tests for
rapid diagnosis of multi-drug resistant TB [11].
The MODS relies on two well-known properties of Myco-
bacterium tuberculosis (MTB): first, the rate of growth in liquid
medium is considerably higher than that on solid medium.
Secondly, the morphology in liquid culture is characteristic
and recognizable, consisting of so-called cord-like structures.
By using an inverted light microscope to examine culture
plates inoculated with sputum, MTB growth can be detected
within 7–10 days, for both smear-positive and -negative sam-
ples, compared with conventional solid culture that takes
3–8 weeks [12,13].
The NRA assay relies on the ability of MTB to reduce
nitrate to nitrite. The presence of nitrite, indicating metabol-
ically active mycobacteria, can easily be detected by the addi-
tion of what is known as the Griess reagent into the culture
tube, producing a visually observed pink to purple colorchange [14]. The NRA test was modified by using Middlebrook
7H9 broth (Difco) as the culture media, since the rate of
growth in liquid medium is considerably quicker than that
on solid medium. As reported previously, results can be avail-
able within 10–14 days when liquid culture media is used.
These studies were, however, based on examination of
microscopy positive sputum samples with a higher content
of bacteria [15].
Materials and methods
Ethical approval for the study was obtained from the research
and ethics committee, of the College of Sciences of Makerere
University (REC 2011-45).
Sample size
The sample size was calculated based on methods described
earlier [16]. It was hypothesized that the culture and molecu-
lar methods would have similar sensitivities and specificities
of 90% and 98%, respectively. The 95% confidence interval was
adopted, and the corresponding Z value of 1.96 in the calcula-
tions, while the precision was set at ±10%. Based on data from
the pilot study, it was expected that approximately 10% of HIV
patients reported smear-negative would have a positive MTB
culture when evaluated by fluorescent microscopy (FM). It
was therefore required that at least 346 smear-negative
patients be enrolled for the full study.
Patient recruitment
Using an observational and cross-sectional study design,
patients with symptoms of TB between March and November
2012 were enrolled in the study. The study patients were in
attendance at an adult out-patient HIV clinic or were admit-
ted to the medical department at Mulago National Referral
Hospital, Kampala, Uganda. At the hospital, patients are
screened for TB using a standard WHO/Ministry of Health
intensified TB case finding form. According to the form, pa-
tients are presumed to have TB if they had a cough for
P2 weeks, with or without fever, night sweats, loss of weight,
or blood-stained sputum. Following consent of the enrolled
patients, they provided a spot and early morning sputum
sample. Patients were excludedwhowere already on TB treat-
ment or on quinolone medication, or were unable to produce
sputum. Detailed HIV care information was obtained from the
patients’ clinical charts and recorded on a standardized case
record form.
Laboratory methods
The collected sputum samples were maintained at 2–4 C in
an ice box at the clinic/ward, and were carried to a closely
located bio-safety level 3, mycobacteriology research labora-
tory, twice daily. The laboratory is quality controlled by the
National TB Reference Laboratory (NTRL).
Unprocessed sputum received in the laboratory was exam-
ined by fluorescent microscopy (FM) using standard auramine
reagent at x40 objective (Olympus CX31 with LED attachment,
Olympus Corporation, Tokyo, Japan). Samples found positive
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ment physicians to initiate TB treatment. Samples found
negative were pooled and underwent further processing as
follows (see Fig. 1): digestion and decontamination with
NALC/NAOH 2%method for 15 min, followed by homogeniza-
tion. The homogenized sample was then centrifuged at 3000g
(Allegra X-12 series) for 15 min to prepare a sediment [14].
The sediment was re-suspended with phosphate buffer (pH
6.8) to make 5 ml. Aliquots of the suspension (0.5 ml) were
inoculated in MGIT and L–J tubes for mycobacteria culture.
Residual aliquots were stored at 4–8 C, batched and later
tested on Xpert, software version 4.0 (1 ml), NRA (0.5 ml)
and MODS (0.1 ml). All tests were performed by trained tech-
nicians blinded to results from the other tests.
For the Xpert MTB/RIF assay, a sample reagent was added
to the processed sample in a 3:1 ratio. The mixture was incu-
bated at room temperature for 15 minutes and was manually
agitated. A total of 1 ml of sample was introduced into an
Xpert MTB/RIF cartridge, which was then loaded into theSputum from HIV patient with presumpt
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Fig. 1 – SpecimenGeneXpert instrument, where the subsequent steps of sample
lysis, nucleic acid extraction, and amplification occurred
automatically. When sufficient residual was available, repeat
testing was carried out when an ‘‘Invalid’’ or ‘‘Error’’ result
was obtained.
The MODS culture was performed in a 24-well tissue
plate. Two wells were used for each processed and quality
control sample. In brief, the MODS media was prepared with
4.7 g Middlebrook 7H9 broth (Difco, Sparks, MD) and 2 ml
glycerol in 900 ml of distilled water. This media was auto-
claved at 121 C for 10 min, cooled to 45 C and 100 ml of
OADC added. This was stored at 4–8 C. Each new batch of
the media was quality checked for sterility by inoculating
on blood agar before use. Next, 800 ll of the Middlebrook
7H9 broth, 100 ll of a cocktail of polymyxin B, Amphotericin
B, Nalidixic acid, trimethoprim and azlocillin (PANTA: BD),
and 100 ll of the processed sample were transferred into
each well giving a final volume of 1 ml/well. 100 ll of a sus-
pension of H37Rv isolate 0.5 McFarland standard for positiveive TB 
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dlebrook 7H9 broth, 100 ll PANTA without sample was used.
The positive and negative growth control wells were
included for each plate. Plates were sealed with tape and
ziplock bags and incubated at 37 C. The plates were exam-
ined under an inverted light microscope at magnifications
of X10 and X40 for cord formation. Initially the examination
was done on days 5, 7 and 14. However, following a preli-
minary analysis of the first 10% of the samples, which
showed only a few wells with detecable growths by day 14,
examination of the rest of the samples (90%) was extended
to day 21. Wells that had rapid overgrowth or clouding were
interpreted as contaminated.
The modified NRA test was performed using Middlebrook
7H9 broth, supplemented with 2 ml of glycerol, 10% OADC,
PANTA (0.6 ml PANTA: 10 ml 7H9media), and 1000 lg of potas-
sium nitrate (KNO3)/ml. The medium was apportioned into
20 ml screw-cap glass tubes in volumes of 7 ml. Next, 500 ll
of the processed sample was inoculated into 3 tubes contain-
ing the above cocktail. Each batch included three correspond-
ing positive growth control (H37Rv isolate) and the negative
growth control (cocktail without sample). The tubes were
incubated at 37 C. On the day of examination, 200 ll of GriessHIV patients with presum
Evaluated by direct
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Valid
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Fig. 2 – Patient flow and test analysis diagram. Pos = Positive. N
Susceptibility assay. NRA = Nitrate Reductase Assay. Xpert = Xpe
tuberculous mycobacteria growth or ‘‘error’’ or ‘‘invalid’’ resultreagent (a solution of hydrochloric acid 50% (vol/vol), sulfanil-
amide 0.2% wt/vol, and N-(1-naphtyl)ethylene-diamine dihy-
drochloride 0.1% (wt/vol) mixed in a ratio of 1:2:2 was added
into each test tube and observed for change of color to
pink-purple. When color change occurred, it was compared
with the prescribed WHO color standard [14]. The NRA was
initially examined on days 5, 7 and 14, also. However, for sim-
ilar reasons for MODS above, examination was extended to
day 21 as well. Tubes that had clouding were interpreted as
contaminated. For the MGIT culture, 0.5 ml of the processed
samples were inoculated following the protocol of Becton
Dickinson, while for L–J, 0.5 ml of the processed sample was
inoculated onto an L–J slant and incubated at 37 C. MGIT cul-
ture tests were read up to day 42 before recording negative
growth, while the L–J culture was read up to day 56. Positive
cultures on MGIT were examined by ZN microscopy to con-
firm the presence of AFB. The Capilia tuberculosis (MPT64) as-
say [17] or PCR IS6110 method were used to determine if
positive MGIT cultures were MTB or Non-Tuberculous Myco-
bacteria (NTM). All tests were interpreted after examination
of the positive and negative controls. The GeneXpert system
has built-in internal quality control for each sample, which
is automatically performed on each run.ptive TB=744 
 FM=601 
Total excluded=143 
-No consent=67 
-Unproductive cough=57 
-On quinolone/anti-TB medication=19 
XPERT MGIT 
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in the case of the Xpert test.
Table 1 – Characteristics of smear-negative patients with
presumptive TB.
Age: years, median (range), [IQR] 34, (18–67), [29–40]
Female: n, (%) 242, (56)
Duration, attendance in Clinic:
Months, median (range), [IQR]
14, (0–78), [1–46]
Percentage, patients on ART: n (%) 263, (61%)
Duration on ART: Months,
median (range), [IQR]
12 (0–72) [1–38]
Most recent CD4 cell absolute
count/mm3: median (range), [IQR]
280 (2–952) [119–439]
IQR = Inter Quartile Range. ART = Anti-retroviral therapy.
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Patients’ clinical data captured on the standardized case re-
cord form was entered periodically into Epi InfoTM, version
3.5. Laboratory data was entered periodically into MS Access
2003. All data were exported to SPSSTM, version 17.0 for analy-
sis. Sensitivity, specificity and positive and negative predictive
values were calculated using MGITas the reference test. Anal-
ysis was performed on a per patient basis. NTM and contam-
inated cultures were excluded from the analysis. Samples
that were reported contaminated on MGIT, and showed no
growth on L–J, were considered as ‘‘no growth’’.
Patient and sample classifications
An HIV patient was considered to have presumptive TB if they
had a cough for two weeks or more with or without history of
coughing blood-stained sputum. Patients with two sputum
samples negative for AFB after microscopy examination and
negative for MTB after culture were defined as smear and cul-
ture negative. Patients with at least one sputum sample posi-
tive for AFB after microscopy examination were defined as
smear-positive pulmonary TB cases, and were not enrolled
into the study. Patients who had an incomplete set of data
for either the evaluated test or culture were defined as inde-
terminate and were excluded from analysis. A smear-positive
sample was defined as one with scanty grade (1 to 10 AFB per
100 fields) or more bacilli. A culture-positive sample was de-
fined as a sample with growth of MTB. A smear-negative pul-
monary TB sample was one with at least two sputum samples
negative for acid-fast bacilli (AFB) that was culture-positive
for MTB.Table 2 – Sensitivity, specificity, positive and negative predictive
reference, including 95% confidence intervals.
MGIT
Test Positive Negative Sensitiv
MODS Positive 10 6 24.4 (12
Negative 31 317
NRA Positive 17 26 41.5 (26
Negative 24 299
Xpert Positive 21 16 48.8 (33
Negative 22 310Results
Patient flow
744 patients were identified with presumptive TB, and 143 of
which were excluded owing to a lack of consent, unproduc-
tive cough or taking anti-TB or quinolone medication (see
Fig. 2). The remaining 601 (81%) were evaluated with fluores-
cent microscopy and 90 were found smear-positive. Of the
remaining smear-negative patients (511), 81 were excluded
because only one sample was examined, leaving 430 patients
with smear-negative results after examination of the second
sample. Of the 430 smear- negative patients, 364 of the 412
had complete results to fill the 2 · 2 table for calculation of
accuracy for MODS; 366 of the 415 for NRA; and 369 of the
411 for Xpert. In regard to MGIT, of the 430 patients, 373
patients had valid results used for calculation of the index
test accuracy, of which 43 detected MTB growth. Index test
results were considered invalid if they were contaminated
or lacked a corresponding valid reference culture result.
Reference culture results were considered invalid if they were
contaminated on both MGIT and L–J, or if positive, had NTM
growth. The demographic characteristics of the 430 smear-
negative patients are summarized in Table 1.
Test accuracy
The sensitivity and specificity were 24.4% and 98.1% for
MODS, 41.5% and 92% for NRA, 48.8% and 95.1% for Xpert,
respectively. The positive predictive values ranged from
39.5% for NRA to 62.5% for MODS. All three tests exhibited
high negative predictive values of above 90%. The summary
of the accuracy of the tests is shown in Table 2.
Discussion
Poor diagnosis of TB is a major obstacle to TB treatment and
control, especially in areas where smear microscopy generally
is the only diagnostic tool. The situation is worse in HIV pa-
tients because the sensitivity of microscopy is even lower in
these patients. Since 2007, new TB diagnostics have been
developed, and WHO has endorsed some of them for rapid
and increased TB diagnosis. The accuracy was evaluated of
two non-commercial rapid culture tests (MODS and NRA)
and one molecular test (Xpert), in detection of smear-negative
TB in HIV patients. The study focused on smear-negative TBvalue of the MODS, NRA and Xpert against MGIT culture as
ity (95% CI) Specificity (95% CI) PPV% NPV%
.4–40.3) 98.1 (96–99.3) 62.5 91.1
.3–57.9) 92 (88.5–94.7) 39.5 92.6
.3–64.5) 95.1 (92.2–97.2) 56.8 96.3
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of TB without conventional culture.
Currently the MODS and NRA are only endorsed for diag-
nosis of multi-drug resistant TB (MDR-TB) either as direct or
indirect tests. The MODS and NRA were selected because
the two tests were found to be highly accurate and the easiest
to adopt in this setting in an earlier study that evaluated
smear-positive patient population [18]. On the other hand,
Xpert was selected because it is the only rapid molecular test
which the WHO has endorsed for TB diagnosis in patient pop-
ulations who are infected with HIV or are smear-negative on
microscopy. Indeed, there are currently major efforts to roll
out the Xpert in selected recipient countries, a number of
them from high HIV-prevalent and resources-constrained set-
tings [19].
A recent survey of published literature showed that infor-
mation about the accuracy of these three tests in the diagno-
sis of smear-negative TB in HIV patients is currently still
inadequate [20,21]. This study provides new information
which would be useful for developing new diagnostic algo-
rithms and define the role of MODS and NRA in TB/HIV man-
agement. This study also provides additional experience on
the performance of the tests as a follow-up to microscopy
in a high HIV-prevalent African population. In turn, this infor-
mation could provide guidance for the further roll-out of the
tests for improved diagnosis of HIV-associated TB, especially
for the smear-negative form.
The sensitivity of MODS was low (24.4%). The sensitivity
was better, but still low, for the NRA (41.5%) and Xpert
(48.8%). All the tests exhibited relatively low andwidely varied
positive predictive values, from 39.5% for NRA to 62.5% for
MODS. On the other hand, all the tests exhibited high speci-
ficity and negative predicative values of above 90%, (Table 2).
The Xpert has previously been reported to detect approxi-
mately 70% of smear-negative TB [10]. However, there is grow-
ing evidence from reports of studies conducted in high HIV
African settings similar to this study setting, indicating that
sensitivity could be lower, ranging from 40% to 50% [22–24].
The researchers of this study are unaware of studies that have
evaluated MODS and NRA for diagnosis of smear-negative TB
in HIV patients, although one recent study on MODS from In-
dia reported sensitivity of 38% for smear-negative TB. The re-
port, however, did not clearly describe the patient population
[25].
A possible explanation for the low sensitivity of the tests is
the advanced immune deficiency of the study patients in
these settings whose median CD4 count was 280/mm3 in this
study (Table 1). Patients with advanced HIV disease usually
have few bacilli in their sputum, which could be below the
detection limits of the tests [9,26]. No difference was seen in
the CD4 count of the patients with positive and negative MGIT
culture for each of the tests when compared. Therefore, the
effect of immune suppression was uniform for all the three
tests (data not shown).
It is also likely that the MODS and NRA had a low sensi-
tivity because samples were examined after batching weekly
following storage in a fridge (4–8 C). Some loss of viability
could therefore have occurred. On the other hand, it has
been shown previously that there is no such effect on Xpert
[27,28], which is not dependent on live bacteria for detection.This study did not determine the effect of this for the MODS
and NRA. Further, ideally, aliquots of the stored samples
should also have been inoculated into MGIT. However, since
there were different technicians that performed the tests, it
was not possible to perform all the tests at the same time.
The feasible practice was to process the collected sputum,
inoculate on culture and batch the rest of the samples for la-
ter testing weekly. This was the only possible workflow that
could be implemented in the laboratory. In addition, the
MODS and NRAwere initially examined up to day14 and later
up to day 21, whereas MGIT and L–J were examined up to 42
and 56 days, respectively. It is likely that more days were re-
quired before interpreting the two tests as negative. How-
ever, it was considered that a period beyond day 14 could
limit the timeliness of these two tests for patient care. The
timeliness would even be more limited if the reading time
got beyond day 21. Lastly, because fluorescent microscopy
was used, which is more sensitive than the commonly used
Ziehl-Neelsen (ZN) method to determine smear-negative
specimens [29], it is likely that in settings where ZN is the
routine microscopy method for TB diagnosis, the tests could
have been found to be more sensitive.
There were 68 patients with positive culture on MGIT, of
which 38% (25/68) were identified as NTM. Although recovery
of NTM is expected with liquid culture systems, the clinical
implications of this have not been evaluated in this setting.
This is important since microscopy, which is the main diag-
nostic tool for TB, cannot differentiate between MTB and
NTM. Therefore, patients infected with NTM could mistak-
enly be labeled as ‘‘chronic’’ TB cases as they may not respond
to standard TB treatment. Such a scenario has been recog-
nized previously from Honduras [30].
Implications of study findings for practice
Since the sensitivity and the positive predictive values of the
tests were relatively low, this implies that additional diagnos-
tic tools such as chest X-ray and conventional culture could
still be critical for a sensitive diagnosis of smear-negative TB
in this population and setting. It should be considered if, for
example, ‘‘smear and Xpert negative’’ TB suspects would need
further evaluation by conventional culture. However, this may
be difficult in practice because of the resource constraints
faced in many low-income settings. Thus, initiation of inap-
propriate TB medications and the associated side effects
would be avoided. For HIV patients, there is additional benefit
as this implies that they can receive other HIV services such
as isoniazid preventive therapy for TB [31,32], and reduce
the need to make several visits to the clinic for investigations
for TB. This would only be necessary if symptoms persist.
Strength of the study
The strength of this study is that it was performed under real
clinical settings, where patients were enrolled prospectively
and consecutively using pre-set inclusion and exclusion crite-
ria. To further reduce bias from sample selection, sputum
samples were also pooled during processing, although this
may not be replicated as standard practice. Secondly, a strat-
egy to back up MGITwith L–J culture was used. This reduced
154 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 2 ( 2 0 1 3 ) 1 4 8 –1 5 5loss of culture results due to MGIT contamination to 7% in
this study compared with an earlier reported range between
8% and 15% [33].
Conclusion
While the Xpert, MODS and NRA have been developed for use
as frontline tests for rapid TB diagnosis, this study found their
sensitivity for the detection of TB in smear-negative HIV pa-
tients to be low. Additional diagnostics such as chest X-ray
and liquid culture could therefore still be required for TB diag-
nosis in this population. Even though the sensitivity was
unfortunately low for all three tests, they showed a high spec-
ificity and were thus useful to correctly confirm TB in sputum
smear-negative HIV patients with suggestive TB symptoms.
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